Lost in translation: Obstacles to translational medicine

被引：117

作者：

Mankoff S.P. ^{[1
]}

Brander C. ^{[2
]}

Ferrone S. ^{[3
]}

Marincola F.M. ^{[4
]}

机构：

[1] Pharmaceutical Division, Intl. Quality/Productivity Center, New York, NY

[2] Partners AIDS Research Center, Mass General Hospital, Harvard Medical School, Boston, MA

[3] Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY

[4] Immunogenetics Section, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD

来源：

Journal of Translational Medicine | / 2卷 / 1期

关键词：

Translational Research; Clinical Scientist; Translational Medicine; Private Capacity; Translational Effort;

D O I：

10.1186/1479-5876-2-14

中图分类号：

学科分类号：

摘要：

When we launched the Journal of Translational Medicine a few months ago, we were interested primarily in exploring scientific consideration of this discipline. However, as editors of JTM, we have been contacted almost daily to discuss the problems faced by scientists and clinicians around the world who are challenging the traditional boundaries of science and medicine. Through these conversations, we have learned that translational medicine is in fact "lost in translation," inspiring much angst, many promises and some Federal appropriations. However, little has been done to substantively promote this important field. Authoritative reviews on the subject are available to the interested reader [1-7]. In this article, we will address JTM's "constituency" to report what we've learned about the obstacles to translational medicine from the myriad of phone conversations and e-mail interactions. ©2004 Mankoff et al; licensee Biomed Central Ltd.

引用

页数：5

共 24 条

[1]

Kagarise M.J., Sheldon G.F., Translational ethics: A perspective for the new millennium, Arch. Surg., 135, pp. 39-45, (2000)

[2]

Dauphinee D., Martin J.B., Breaking down the walls: Thoughts on the scholarship of integration, Acad. Med., 75, pp. 881-886, (2000)

[3]

Bristow R.G., Recommendations for the future of translational radiobiology research: A Canadian perspective, Radiother. Oncol., 70, pp. 159-164, (2004)

[4]

Ioannidis J.P., Materializing research promises: Opportunities, priorities and conflicts in translational medicine, J. Transl. Med., 2, (2004)

[5]

Buxton D.B., Lee S.C., Wickline S.A., Ferrari M., Circulation, 108, pp. 2737-2742, (2003)

[6]

Gamulin S., Impact of molecular medicine on pathophysiology, medical practice, and medical education, Croat. Med. J., 44, pp. 374-385, (2003)

[7]

Sung N.S., Crowley Jr. W.F., Genel M., Salber P., Sandy L., Sherwood L.M., Et al., Central challenges facing the national clinical research enterprise, JAMA, 289, pp. 1278-1287, (2003)

[8]

Laboratory Research Division workshop on the role of in vivo pre-clinical models in the development of contemporary cancer therapeutics, Eur. J. Cancer., 37, pp. 1976-1980, (2001)

[9]

Jin P., Wang E., Polymorphism in clinical immunology. From HLA typing to immunogenetic profiling, J. Transl. Med., 1, (2003)

[10]

Hughes G.C., Post M.J., Simons M., Annex B.H., Translational physiology: Porcine models of human coronary artery disease: Implications for preclinical trials of therapeutic angiogenesis, J. Appl. Physiol., 94, pp. 1689-1701, (2003)

← 1 2 3 →